Entrada Therapeutics (TRDA) Stock Price, News & Analysis

Company Overview

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity. Lead programs target lysosomal storage disorders and neuromuscular diseases, with preclinical candidates optimized for tissue tropism and intracellular uptake. Entrada’s technology is designed to be modular, allowing for potential application across multiple therapeutic areas.

Founded in Cambridge, Massachusetts, Entrada leverages a team with expertise in protein engineering, cell biology and drug delivery. The company serves patients globally by pursuing regulatory filings in key markets and collaborating with academic partners and contract development organizations. Through continued platform development and strategic partnerships, Entrada seeks to bring novel intracellular therapies from lab to clinic.

Key Stats

• Today's Range: $7.00 to $7.17
• 50-Day Range: $5.83 to $7.78
• 52-Week Range: $5.02 to $16.45
• Volume: 341,729 shs
• Average Volume: 261,480 shs
• Market Capitalization: $277.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.75
• Consensus Rating: Moderate Buy

Entrada Therapeutics Stock Analysis - MarketRank™

Entrada Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 501st out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Entrada Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Entrada Therapeutics has a consensus price target of $17.75, representing about 148.9% upside from its current price of $7.13.

Amount of Analyst Coverage

Entrada Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Entrada Therapeutics are expected to grow in the coming year, from ($4.03) to ($3.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Entrada Therapeutics is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Entrada Therapeutics is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Entrada Therapeutics has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.72% of the float of Entrada Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Entrada Therapeutics has a short interest ratio ("days to cover") of 6.15.

Change versus previous month

Short interest in Entrada Therapeutics has recently increased by 10.42%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Entrada Therapeutics does not currently pay a dividend.

Dividend Growth

Entrada Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.47

News Sentiment

Entrada Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Entrada Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for TRDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,819,524.00 in company stock.

Percentage Held by Insiders

9.49% of the stock of Entrada Therapeutics is held by insiders.

Percentage Held by Institutions

86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/05/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TRDA
• CIK: 1689375
• Web: www.entradatx.com
• Phone: 857-520-9158
• Fax: N/A
• Employees: 110
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Entrada Therapeutics: $17.75
• High Price Target: $23.00
• Low Price Target: $11.00
• Potential Upside/Downside: +148.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$143.75 million
• Net Margins: -3,537.73%
• Pretax Margin: -3,520.25%
• Return on Equity: -57.61%
• Return on Assets: -46.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.89
• Quick Ratio: 10.89

Sales & Book Value

• Annual Sales: $25.42 million
• Price / Sales: 10.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.99 per share
• Price / Book: 1.19

Miscellaneous

• Outstanding Shares: 38,940,000
• Free Float: 35,242,000
• Market Cap: $277.64 million
• Optionable: Optionable
• Beta: -0.25